TriSalus Life Sciences (NASDAQ:TLSI) Issues Quarterly Earnings Results

by · The Cerbat Gem

TriSalus Life Sciences (NASDAQ:TLSI – Get Free Report) posted its earnings results on Thursday. The company reported ($0.96) EPS for the quarter, missing the consensus estimate of ($0.17) by ($0.79), Zacks reports. The company had revenue of $11.57 million during the quarter, compared to analyst estimates of $11.76 million. TriSalus Life Sciences updated its FY 2025 guidance to EPS.

TriSalus Life Sciences Trading Up 4.4%

Shares of TLSI traded up $0.20 during mid-day trading on Friday, reaching $4.59. The company’s stock had a trading volume of 120,582 shares, compared to its average volume of 78,806. The stock has a market cap of $228.64 million, a PE ratio of -3.89 and a beta of 0.47. TriSalus Life Sciences has a 52 week low of $3.42 and a 52 week high of $5.88. The company’s fifty day moving average price is $4.72 and its two-hundred day moving average price is $4.89.

Analyst Ratings Changes

Several analysts have weighed in on the stock. Weiss Ratings reissued a “sell (d-)” rating on shares of TriSalus Life Sciences in a research note on Wednesday, October 8th. Wall Street Zen lowered shares of TriSalus Life Sciences from a “hold” rating to a “sell” rating in a report on Sunday, September 28th. Four analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $10.50.

Check Out Our Latest Analysis on TLSI

Institutional Trading of TriSalus Life Sciences

Large investors have recently added to or reduced their stakes in the stock. JPMorgan Chase & Co. raised its holdings in TriSalus Life Sciences by 35,804.8% in the 2nd quarter. JPMorgan Chase & Co. now owns 7,540 shares of the company’s stock worth $41,000 after purchasing an additional 7,519 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. purchased a new stake in TriSalus Life Sciences in the second quarter worth about $47,000. New York State Common Retirement Fund purchased a new position in shares of TriSalus Life Sciences during the 2nd quarter worth approximately $108,000. Goldman Sachs Group Inc. bought a new stake in shares of TriSalus Life Sciences in the 1st quarter worth approximately $187,000. Finally, Squarepoint Ops LLC purchased a new stake in shares of TriSalus Life Sciences in the 3rd quarter worth approximately $343,000. Institutional investors own 2.58% of the company’s stock.

About TriSalus Life Sciences

(Get Free Report)

TriSalus Life Sciences, Inc, a medical technology company, researches, develops, and sells drug delivery technologies and immune-oncology therapeutics for the treatment of liver and pancreatic cancer. The company offers Pressure Enabled Drug Delivery infusion systems, such as the TriNav infusion system, which is used in transarterial radioembolization and chemoembolization procedures for patients with liver cancer and metastases; and the Pancreatic Retrograde Venous Infusion device, which is in Phase 1 clinical trial, for locally advanced pancreatic cancer.

Featured Articles